Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
(Source: illumina.com) November 2024: Ascendis Pharma licensed its TransCon technology to Novo Nordisk for metabolic and cardiovascular drug development, including a monthly GLP-1 agonist for obesity and diabetes
In the LEADER trial, over 9,340 patients with type 2 diabetes and high cardiovascular disease risk underwent randomization to liraglutide or placebo and were followed for a median of 3.8 years resulting in a 13% risk reduction in a combined endpoint of death from cardiovascular cause, nonfatal myocardial infarction, or nonfatal stroke [46]
Dysregulation of these pathways is essential to supporting the uncontrolled proliferation of cancer cells 1,2
PBS Key take-aways Step-before-GLP-1 PBS now demands that an SGLT2-i be trialled (unless contraindicated) and either: caused intolerance, or failed to achieve 0.5 % (5 mmol/mol) HbA1c reduction after 6 months
10.1016/j.tibs.2017.11.004 261 SolimanH
View Study [2]"Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide" Enebo LB et al., 2021 Finding: Phase 1b trial demonstrated that combining cagrilintide with semaglutide 2.4mg resulted in up to 17.1% weight loss at 20 weeks, with the combination being well-tolerated
US$ 23.17
US$ 20.90
US$ 21.70
